Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy

BACKGROUND: Demethylation process is necessary for the expression of various factors involved in chemotherapy cytotoxicity or resistance. Platinum-resistant cells may have reduced expression of the copper/platinum transporter CTR1. We hypothesized that azacitidine and oxaliplatin combination therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsimberidou, Apostolia M, Said, Rabih, Culotta, Kirk, Wistuba, Ignacio, Jelinek, Jaroslav, Fu, Siqing, Falchook, Gerald, Naing, Aung, Piha-Paul, Sarina, Zinner, Ralph, Siddik, Zahid H, He, Guangan, Hess, Kenneth, Stewart, David J, Kurzrock, Razelle, Issa, Jean-Pierre J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4371799/
https://www.ncbi.nlm.nih.gov/pubmed/25806091
http://dx.doi.org/10.1186/s13148-015-0065-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4371799/
https://www.ncbi.nlm.nih.gov/pubmed/25806091
http://dx.doi.org/10.1186/s13148-015-0065-5

Ejemplares similares